Expert Details ‘Exciting’ Bispecific Combos for Lymphoma

Video

Combining bispecific antibodies with other agents such as R-CHOP and R-CHP for various subtypes of lymphoma has the potential to produce exciting results, according to an expert from Dana-Farber Cancer Institute.

Research assessing bispecific antibodies in combination with chemotherapy agents, other anti-CD20 antibodies, or agents that do not cause bone marrow suppression has the potential to produce exciting results in patients diagnosed with lymphoma, according to Ann S. LaCasce, MD, MMSc.

In an interview with CancerNetwork®, LaCasce, institute physician, Fellowship Program chair for Hematology/Oncology, and director of Hematology/Oncology fellowship at Dana-Farber Cancer Institute and Massachusetts General Brigham Cancer Center, as well as an associate professor of medicine at Harvard Medical School, highlighted the potential of these combinations in several disease subtypes, from those with diffuse large B-cell lymphoma to first-line indolent follicular lymphoma.

She explains that it may be possible to see durable remissions following treatment with these combinations—a question that only ongoing research efforts can work to answer.

Transcript:

There are a lot of ongoing studies with bispecific antibodies—both CD20 and CD3. We have 4 main compounds that are currently in clinical trials; mosunetuzumab-axgb [Lunsumio] has been approved in the United States in follicular lymphoma, [for example]. The studies that I’m excited about are the ones that are combining these agents up-front in various subtypes of lymphoma.

Particularly, in diffuse large B-cell lymphoma, they’re being combined with R-CHOP [rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine sulfate, and prednisone] and with polatuzumab vedotin-piiq [Polivy]plus R-CHP [rituximab, cyclophosphamide, doxorubicin, and prednisone]. Giving these drugs when patients have not had chemotherapy that may impact their T-cell function; is going to be interesting.

Looking at adding these agents in the up-front setting and indolent lymphomas like follicular lymphoma in combination with other CD20 antibodies and/or with lenalidomide [Revlimid] or medications that we think of as not causing bone marrow suppression is very exciting. Perhaps we'll see patients have durable remissions. I’m looking forward to seeing how this all plays out across all different subtypes of lymphoma.

Reference

FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. News release. FDA. December 22, 2022. Accessed January 27, 2023. https://bit.ly/3WE5Ze5

Related Videos
The education of patients on identifying and reporting adverse effects is a critical part of effective toxicity management.
One role of a physician assistant is to help patients understand their treatment and the results they’re presented with.
Adverse effect management is a concern for clinicians when administering follicular lymphoma treatment, and the use of targeted pathways may help mitigate them.
Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Kami J. Maddocks, MD, Shows Optimism for Future Development of Cellular Therapies in Lymphoma
Kami J. Maddocks, MD, Reviews Ongoing Research Into Bispecific Antibodies and Other New Treatment Combinations for Lymphoma
Kami J. Maddocks, MD, Talks Updates in Hodgkin Lymphoma Using Brentuximab Vedotin and PD-1 Inhibitors
Related Content